Our Pipeline
Unlocking value in high-potential therapeutic areas
Transpire Bio is applying its inhalation technologies to areas with the greatest therapeutic and commercial potential, including:
- Attractive markets with sizable unmet needs
- Molecules with a known mechanism of action and a well-defined clinical benefit
- Clinical applications where inhalation is most likely to add value
- Areas with a well-defined regulatory pathway
Unlocking value in high-potential therapeutic areas
Transpire Bio is applying its inhalation technologies to areas with the greatest therapeutic and commercial potential, including:
- Attractive markets with sizable unmet needs
- Molecules with a known mechanism of action and a well-defined clinical benefit
- Clinical applications where inhalation is most likely to add value
- Areas with a well-defined regulatory pathway
Our target clinical applications
Idiopathic Pulmonary Fibrosis (IPF)
~$28 billion US addressable market
Multi-asset pipeline to address unmet needs in the market for IPF and related interstitial lung diseases (ILDs), including a new chemical entity and a partnered co-developed asset.
Learn More
Clinical application
Idiopathic Pulmonary Fibrosis (IPF) is an orphan lung disease that causes shortness of breath and occurs when lung tissue becomes damaged/scarred. The median survival is 2-3 years.1
Unmet need
Current treatments have challenges due to GI adverse events and liver toxicity.
Market size
IPF is a sizable, growing market, accounting for 1/3 of the 650,0002 people affected by ILDs in the US. It has a total US addressable market of ~$28 billion with a forecasted 6.1% CAGR through 2034.3
Our pipeline
Status: Clinical
Transpire Bio is advancing three inhaled assets through clinical development:
- In-House Program #1 – Inhaled PDE4b inhibitor with an expected improved safety profile, reduced drug interactions, and maximized therapeutic window
- In-House Program #2 – A NCE PDE4 inhibitor and potential best-in-class molecule with multiple mechanisms of action
- Co-Development Program #3 – Established multi-billion-dollar molecule franchise with applications in PAH, IPF, and ILD—to be delivered by our Springboard™ platform
- Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-440. doi: 10.1164/rccm.201006-0894CI.
- Maher TM. Interstitial lung disease: a review. JAMA. 2024;331(19):1655-1655. doi: 10.1001/jama.2024.3669.
- Idiopathic pulmonary fibrosis market size to reach USD 6,906.1 million by 2034, impelled by strong drug pipeline. BioSpace. Published August 2, 2024. Accessed June 3, 2025.
Learn More
Clinical application
Idiopathic Pulmonary Fibrosis (IPF) is an orphan lung disease that causes shortness of breath and occurs when lung tissue becomes damaged/scarred. The median survival is 2-3 years.1
Unmet need
Current treatments have challenges due to GI adverse events and liver toxicity.
Market size
IPF is a sizable, growing market, accounting for 1/3 of the 650,0002 people affected by ILDs in the US. It has a total US addressable market of ~$28 billion with a forecasted 6.1% CAGR through 2034.3
Our pipeline
Status: Clinical
Transpire Bio is advancing three inhaled assets through clinical development:
- In-House Program #1 – Inhaled PDE4b inhibitor with an expected improved safety profile, reduced drug interactions, and maximized therapeutic window
- In-House Program #2 – A NCE PDE4 inhibitor and potential best-in-class molecule with multiple mechanisms of action
- Co-Development Program #3 – Established multi-billion-dollar molecule franchise with applications in PAH, IPF, and ILD—to be delivered by our Springboard™ platform
- Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-440. doi: 10.1164/rccm.201006-0894CI.
- Maher TM. Interstitial lung disease: a review. JAMA. 2024;331(19):1655-1655. doi: 10.1001/jama.2024.3669.
- Idiopathic pulmonary fibrosis market size to reach USD 6,906.1 million by 2034, impelled by strong drug pipeline. BioSpace. Published August 2, 2024. Accessed June 3, 2025.
Learn More
Clinical application
Parkinson’s Disease Psychosis is a neurodegenerative disorder that primarily affects the dopaminergic (motor) system. It results in non-motor symptoms that are debilitating and develop in the later stages of Parkinson’s Disease.
Unmet need
Only one FDA-approved product is available, with mixed KOL feedback on its efficacy.
Market size
A large and growing population, accounting for up to 60%1 of the ~1,100,000 people living in the US with Parkinson’s Disease.2 It has a total US addressable market of ~$29 billion.3
Our pipeline
Status: Phase 1 Clinical Study Starting in 2025
Leveraging our high-potency, clinical-grade, inhaled CBD formulation platform, proof-of-concept has been established. Inhaled delivery supports the targeting of known pathways and processes, and multiple preclinical studies demonstrate the safe delivery of high concentrations via inhalation.
- Mansuri Z, Reddy A, Vadukapuram R, Trivedi C, Amara A. Pimavanserin in the treatment of Parkinson’s disease psychosis: meta-analysis and meta-regression of randomized clinical trials. Innov Clin Neurosci. 2022;19(1-3):46-51. PMID: 35382074; PMCID: PMC8970241.
- Statistics: get informed about Parkinson’s disease with these key numbers. Parkinson’s Foundation. Accessed June 3, 2025.
- Parkinson’s disease psychosis market size, analysis, industry statistics and latest insights till 2034. EIN Presswire. Published April 10, 2024. Accessed June 3, 2025.
Parkinson’s Disease Psychosis
~$29 billion US addressable market
Inhaled delivery supports the targeting of known pathways and processes, and multiple preclinical studies demonstrate the safe delivery of high concentrations via inhalation.
Learn More
Clinical application
Parkinson’s Disease Psychosis is a neurodegenerative disorder that primarily affects the dopaminergic (motor) system. It results in non-motor symptoms that are debilitating and develop in the later stages of Parkinson’s Disease.
Unmet need
Only one FDA-approved product is available, with mixed KOL feedback on its efficacy.
Market size
A large and growing population, accounting for up to 60%1 of the ~1,100,000 people living in the US with Parkinson’s Disease.2 It has a total US addressable market of ~$29 billion.3
Our pipeline
Status: Phase 1 Clinical Study Starting in 2025
Leveraging our high-potency, clinical-grade, inhaled CBD formulation platform, proof-of-concept has been established. Inhaled delivery supports the targeting of known pathways and processes, and multiple preclinical studies demonstrate the safe delivery of high concentrations via inhalation.
- Mansuri Z, Reddy A, Vadukapuram R, Trivedi C, Amara A. Pimavanserin in the treatment of Parkinson’s disease psychosis: meta-analysis and meta-regression of randomized clinical trials. Innov Clin Neurosci. 2022;19(1-3):46-51. PMID: 35382074; PMCID: PMC8970241.
- Statistics: get informed about Parkinson’s disease with these key numbers. Parkinson’s Foundation. Accessed June 3, 2025.
- Parkinson’s disease psychosis market size, analysis, industry statistics and latest insights till 2034. EIN Presswire. Published April 10, 2024. Accessed June 3, 2025.
Brain Tumors/Glioblastoma
~$10 billion US addressable market
Clinical-grade, inhaled therapeutic targeting a category with no therapeutic advancements in the past two decades, and that currently has poor patient survivability.
Learn More
Clinical application
Glioblastoma (GBM) is a malignant tumor affecting the brain or spine, with a median survival of 15-18 months.
Unmet need
There have been no therapeutic advancements in the past two decades, with the standard of care being maximal surgical resection, radiotherapy, and chemotherapy. Challenges with conventional therapy resistance and neurotoxicity persist.
Market size
A large and growing population, representing roughly half (~12,000) of the 24,000 people in the US with malignant brain tumors.1 It has a total US addressable market of ~$10 billion.2
Our pipeline
Status: Phase 1 Clinical Study Starting in 2025
Leveraging our high-potency, clinical-grade, inhaled, CBD formulation platform, proof-of-concept has been established via an animal model. Animals treated with Transpire Bio’s inhaled drug demonstrated a significant reduction in tumor size and improved survival.
- Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25(12 suppl. 2):iv1-iv99. doi: 10.1093/neuonc/noad149.
- Glioblastoma multiforme treatment market—by treatment, by drug class, by dosage form, by gender, by end use—global forecast, 2024–2032. Global Market Insights. Published June 2024. Accessed June 3, 2025.
Learn More
Clinical application
Glioblastoma (GBM) is a malignant tumor affecting the brain or spine, with a median survival of 15-18 months.
Unmet need
There have been no therapeutic advancements in the past two decades, with the standard of care being maximal surgical resection, radiotherapy, and chemotherapy. Challenges with conventional therapy resistance and neurotoxicity persist.
Market size
A large and growing population, representing roughly half (~12,000) of the 24,000 people in the US with malignant brain tumors.1 It has a total US addressable market of ~$10 billion.2
Our pipeline
Status: Phase 1 Clinical Study Starting in 2025
Leveraging our high-potency, clinical-grade, inhaled, CBD formulation platform, proof-of-concept has been established via an animal model. Animals treated with Transpire Bio’s inhaled drug demonstrated a significant reduction in tumor size and improved survival.
- Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25(12 suppl. 2):iv1-iv99. doi: 10.1093/neuonc/noad149.
- Glioblastoma multiforme treatment market—by treatment, by drug class, by dosage form, by gender, by end use—global forecast, 2024–2032. Global Market Insights. Published June 2024. Accessed June 3, 2025.
Learn More
Clinical application
GLP-1 agonists have become the standard of care in the treatment of obesity to achieve and maintain clinically-relevant weight loss, and are also used for glucose management in Type 2 diabetes.
Unmet need
Current GLP-1 drugs experience patient adherence issues due to GI and other side effects, and cost. Additionally, the latest GLP-1 drugs are not suitable for rapid onset, short-acting use during maintenance.
Market size
Worldwide, more than 800 million people have obesity1, including ~42% of US adults (>145 million)2 and ~20% of US adolescents and children (~15 million).3 It has a total US addressable market of ~$1.8 trillion.4
Our pipeline
Status: Preclinical
An inhalable GLP-1 has the potential to address unmet needs—especially for those in the therapy maintenance phase—by offering a faster acting, more tolerable, lower cost drug. We have identified an ideal API and delivery device, and are in preclinical development.
- News release. World Obesity Day 2022—accelerating action to stop obesity. World Health Organization. Published March 4, 2022. Accessed June 3, 2025.
- State of obesity 2022: better policies for a healthier America. Trust for America’s Health. Published September 27, 2022. Accessed June 3, 2025.
- Childhood obesity facts. CDC. Published April 2, 2024. Accessed June 3, 2025.
- U.S. weight management market size, share & trends analysis report by function (diet (meals, beverages, supplements), fitness equipment (cardiovascular training equipment), surgical equipment, services), and segment forecasts, 2024–2030. Grand View Research. Accessed June 3, 2025.
Obesity & Diabetes
~$1.8 trillion US addressable market
Inhaled GLP-1 offering to address gaps in the current market for the maintenance of weight loss and diabetes management.
Learn More
Clinical application
GLP-1 agonists have become the standard of care in the treatment of obesity to achieve and maintain clinically-relevant weight loss, and are also used for glucose management in Type 2 diabetes.
Unmet need
Current GLP-1 drugs experience patient adherence issues due to GI and other side effects, and cost. Additionally, the latest GLP-1 drugs are not suitable for rapid onset, short-acting use during maintenance.
Market size
Worldwide, more than 800 million people have obesity1, including ~42% of US adults (>145 million)2 and ~20% of US adolescents and children (~15 million).3 It has a total US addressable market of ~$1.8 trillion.4
Our pipeline
Status: Preclinical
An inhalable GLP-1 has the potential to address unmet needs—especially for those in the therapy maintenance phase—by offering a faster acting, more tolerable, lower cost drug. We have identified an ideal API and delivery device, and are in preclinical development.
- News release. World Obesity Day 2022—accelerating action to stop obesity. World Health Organization. Published March 4, 2022. Accessed June 3, 2025.
- State of obesity 2022: better policies for a healthier America. Trust for America’s Health. Published September 27, 2022. Accessed June 3, 2025.
- Childhood obesity facts. CDC. Published April 2, 2024. Accessed June 3, 2025.
- U.S. weight management market size, share & trends analysis report by function (diet (meals, beverages, supplements), fitness equipment (cardiovascular training equipment), surgical equipment, services), and segment forecasts, 2024–2030. Grand View Research. Accessed June 3, 2025.
Learn More
Clinical application
CBD (cannabidiol) benefits have been established and has multiple potential CNS and oncology applications, including:
- CNS: seizure disorders, pain, anxiety, depression, PTSD, Tourette’s
- Oncology: brain cancers, lung cancers, leukemia
Unmet need
There is currently only one FDA-approved CBD product. Historically, clinical applications have been limited due to challenges in formulating high-dose CBD due to its inherent:
- Low potency
- Low oral bioavailability
- Variability of plant-based CBD
Our pipeline
Status: Preclinical
We have successfully developed a high-potency, high-efficiency, fully synthetic, clinical-grade, inhaled CBD formulation that can serve as a platform for multiple in-house or partnered clinical applications.
- Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder. Front Neurosci. 2018;12. doi: 10.3389/fnins.2018.00502.
- O’Sullivan SE, Jensen SS, Nikolajsen GN, Bruun HZ, Bhuller R, Hoeng J. The therapeutic potential of purified cannabidiol. J. Cannabis Res. 2023;5(21). doi: 10.1186/s42238-023-00186-9.
- Talebi M, Sadoughi MM, Ayatollahi SA, et al. Therapeutic potentials of cannabidiol: focus on the Nrf2 signaling pathway. Biomed Pharmacother. 2023;168:115805. doi: 10.1016/j.biopha.2023.115805
Multi-Indication Platform
Multiple high-potential markets
Fully developed, high-purity, high-payload, clinical-grade, inhaled CBD formulation platform that has multiple clinical applications for central nervous system (CNS) disorders and oncology.
Learn More
Clinical application
CBD (cannabidiol) benefits have been established and has multiple potential CNS and oncology applications, including:
- CNS: seizure disorders, pain, anxiety, depression, PTSD, Tourette’s
- Oncology: brain cancers, lung cancers, leukemia
Unmet need
There is currently only one FDA-approved CBD product. Historically, clinical applications have been limited due to challenges in formulating high-dose CBD due to its inherent:
- Low potency
- Low oral bioavailability
- Variability of plant-based CBD
Our pipeline
Status: Preclinical
We have successfully developed a high-potency, high-efficiency, fully synthetic, clinical-grade, inhaled CBD formulation that can serve as a platform for multiple in-house or partnered clinical applications.
- Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder. Front Neurosci. 2018;12. doi: 10.3389/fnins.2018.00502.
- O’Sullivan SE, Jensen SS, Nikolajsen GN, Bruun HZ, Bhuller R, Hoeng J. The therapeutic potential of purified cannabidiol. J. Cannabis Res. 2023;5(21). doi: 10.1186/s42238-023-00186-9.
- Talebi M, Sadoughi MM, Ayatollahi SA, et al. Therapeutic potentials of cannabidiol: focus on the Nrf2 signaling pathway. Biomed Pharmacother. 2023;168:115805. doi: 10.1016/j.biopha.2023.115805
